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ABSTRACT
Renal sympathetic denervation (RSD) has emerged as an ad-
junct strategy in the treatment of resistant hypertension. Several 
other clinical conditions are characterized by sympathetic 
hyperactivity and could theoretically benefit from RSD. We 
report the first case of RSD performed in Brazil in a patient 
with Chagas’ disease and refractory arrhythmia, treated by the 
EnligHTN® multi-electrode catheter.
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RESUMO
Denervação Simpática Renal:  
um Novo Cateter em um Novo Cenário
A denervação simpática renal (DSR) surgiu como uma estraté-
gia terapêutica adjunta no tratamento da hipertensão arterial 
sistêmica resistente. Diversas outras condições clínicas cursam 
com hiperatividade simpática, às quais, teoricamente, a DSR 
seria benéfica. Relatamos o primeiro caso realizado no Brasil 
de DSR em paciente com doença de Chagas e arritmia refra-
tária, tratada por meio do cateter multieletrodo EnligHTN®.
DESCRITORES: Simpatectomia. Artéria renal. Doença de 
Chagas. Taquicardia ventricular.
R enal sympathetic denervation (RSD) has emerged as an adjunct, safe, and effective therapeutic strategy in the treatment of resistant systemic arterial hyper-
tension (SAH). Several other clinical conditions occur 
with sympathetic hyperactivity, to which, theoretically, 
RSD would be beneficial, which is a matter under 
investigation. There is little evidence of the effects of 
this procedure in the context of cardiac arrhythmias. 
Sympathetic hyperactivity significantly contributes 
to the development of ventricular arrhythmias.1 RSD 
has shown to reduce the spillover of norepinephrine 
by 42% and neuromuscular efferent sympathetic acti-
vity by 66%.2
The authors report the first case treated in Brazil 
with a dedicated system for RSD in a patient with 
Chagas disease and refractory ventricular arrhythmia, 
aiming to reduce episodes of ventricular tachycardia/
fibrillation (VT/VF).
CASE REPORT 
A 56-year-old female patient, from the state of Bahia 
and living in São Paulo, with SAH, started receiving 
medical care at this service in 1992, with complaints 
of fatigue and palpitations. The diagnosis of Chagas 
disease was based on the results of indirect immu-
nofluorescence. The electrocardiogram (ECG) showed 
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sinus rhythm, low QRS voltage in the frontal plane, 
and isolated ventricular extrasystoles. The outpatient 
follow-up disclosed progressive increase in density of 
ventricular extrasystoles and several episodes of non-
sustained VT, in spite of the use of amiodarone and 
diltiazem. In 2007, during an investigation of syncope, 
at the 24-hour Holter she had 636 VT episodes, with 
the longest being 53 beats at a rate of 200 systoles 
per minute. In 2009, an electrophysiological study was 
conducted, and ablation of the arrhythmogenic focus 
was performed successfully. However, she had two 
other outbreaks of sustained VT, and an implantable 
cardioverter defibrillator (ICD) was indicated. Despite 
optimization of the antiarrhythmic therapy (amiodarone 
400 mg/day and beta-blockers at maximum tolerated 
dose), the patient had three episodes of sustained VT 
in a three-month period, all refractory to the rapid 
programmed stimulation therapy, requiring defibrillation 
by the device. Ablation of the renal arteries was then 
indicated, in an attempt to reduce the arrhythmic burden. 
Procedure
The procedure was approved by the local research 
ethics committee and the patient signed the informed 
consent form. The right femoral artery was punctured after 
local anesthesia with 2% lidocaine and sedation/analgesia 
with narcotics and opioids, followed by introduction of a 
55 cm 8F sheath, equipped with the EnligHTN® (St. Jude 
Medical) ablation system, with the aid of a 0.035-inch 
guide wire. Unfractionated heparin was administered in-
travenously (100 IU/kg). An abdominal aortography was 
performed with a 6F pigtail catheter to check for possible 
accessory renal arteries, using low-osmolarity ionic contrast 
medium (Figure 1A). Selective renal angiography (Figures 
1B and 1C) was performed through the sheath after intra-
arterial administration of nitroglycerin (200 mcg), followed 
by the measurement of diameters and extensions of renal 
arteries by online quantitative angiography. The right renal 
artery (RRA) measured 4.7/36 mm and the left (LRA), 5.2/ 
50 mm. A 16-mm multielectrode ablation catheter was 
then selected and positioned in the distal RRA through 
the sheath (Figures 2A and 2B). Four applications of ra-
diofrequency (RF) were performed sequentially and then 
the catheter was removed and rotated at approximately 
45° for other four applications, as recommended by the 
manufacturer (Figure 2C). Finally, a control angiography 
was performed after administration of nitroglycerin (200 
mcg), for investigation of vascular integrity. The same 
procedure was performed in the LRA. There were no 
complications. The total fluoroscopy time was 8 minutes 
and 90 mL of contrast medium were used. 
The sheath was removed when the activated clotting 
time (ACT) reached < 200/s, followed by hemostasis with 
manual compression for 20 minutes. Ambulation was 
allowed after a four-hour period of rest. The patient was 
discharged on the following day, without complications 
at the puncture site nor any others. 
Clinical follow-up involved the periodic assessment 
of the ICD, which showed no sustained ventricular ar-
rhythmias or need for therapy by the device during the 
two-month follow-up to this date. 
The EnligHTN® system
Consisting of a sheath, RF generator, and catheter 
(Figure 3), the EnligHTN® is the first dedicated system 
for RSD approved by the Brazilian National Health 
Surveillance Agency (Agência Nacional de Vigilância 
Sanitária – ANVISA) for clinical use in Brazil. It is con-
venient system, as it has a multielectrode catheter, which 
greatly facilitates the procedure, requiring less catheter 
manipulation and allowing the RF applications to be 
more evenly distributed, when compared to a single 
electrode catheter. The technical specifications for the 
EnligHTN® system are shown in Table 1.
The sheath has an 8F caliber, is 55 cm long, and 
includes two appropriate distal curvatures to facilitate 
selective catheterization of the renal arteries and abla-
tion of the catheter passage (Figure 3A).
Figure 1. (A) Abdominal aortography with pig-tail catheter to assess the presence of possible accessory renal arteries; (B) Selective angiography of 
the right renal artery, and (C) Selective angiography of the left renal artery after intra-arterial administration of nitroglycerin (200 mcg).
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The RF generator has a digital display to control 
power, temperature, impedance, and time of appli-
cation, in addition to displaying the number of the 
treatment being performed (Figure 3B). Per protocol, 
two treatments are performed at distinct sites in each 
renal artery, one distal and one more proximal. Each 
treatment consists of the sequential release of RF by 
one of the four electrodes, each lasting 90 seconds; 
thus, six minutes are required for each treatment, 12 
minutes for each renal artery, and 24 minutes is the 
total time of energy application.
The ablation catheter has a compatible caliber with 
the 8F sheath and the four electrodes at its distal end are 
Figure 2. (A) A 16-mm multielectrode ablation catheter positioned at the distal right renal artery through the sheath, with the basket still closed. (B) 
The basket is open, promoting proper contact of the electrodes with the vascular wall for effective ablation of renal nerves. (C) After four sequential 
RF applications, the catheter was withdrawn and rotated at about 45° for four other applications.
Figure 3. EnligHTN® dedicated system for renal sympathetic denervation comprising: (A) 8F renal sheath; (B) RF generator, and (C) multielectrode 
ablation catheter.
TABLE 1  
Technical specifications of the EnligHTN® system for renal sympathetic denervation
Approval by the Brazilian National Health Surveillance Agency October 2013
Energy Radiofrequency
Maximum released power 6 watts
Maximum temperature allowed in the electrode 75°C
Number of electrodes 4
Sizes of baskets/diameter of the renal arteries 16 mm/4.0-6.0 mm
18 mm/5.5-8.0 mm
Caliber of catheter Compatible with 8F sheath
Time of radiofrequency application in each electrode 90 seconds
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arranged in the shape of a basket (Figure 3C). There are two 
sizes of baskets: one larger, of 18 mm, for the treatment 
of arteries between 4.0 mm and 6.0 mm of diameter, and 
a smaller basket, of 16 mm, for the treatment of arteries 
between 5.5 mm and 8.0 mm in diameter. Its tip is flexible 
and designed to be non-traumatic. The knob controls flex-
ion (with longitudinal movement) and the opening/closing 
of the basket (with clockwise/counterclockwise rotational 
motion). The basket must be introduced closed into renal 
artery, and promptly opened as soon as it is positioned 
precisely at the site of RF application, providing adequate 
contact with the vascular wall for appropriate delivery 
of energy and consequent ablation of renal nerves. After 
the first treatment, the basket is closed, and the catheter 
is pulled for 10 mm and rotated at 45° for the second 
sequence of RF application. After being positioned in the 
appropriate location, using fluoroscopy and radiological 
contrast, the basket is opened once more. After the sec-
ond treatment, the basket is closed and the catheter is 
removed. Angiographic control after RSD is performed to 
assess vascular integrity. The same procedure is repeated 
in the contralateral renal artery. After the procedure, the 
sheath should be withdrawn with routine care.
The second generation of the EnligHTN® system, 
now available in Europe, has significantly shortened the 
total duration of RF application: from 24 to 4 minutes, 
as the four electrodes are used simultaneously for 60 
seconds, totaling 2 minutes for each artery; thus, there is 
a total of 4 minutes of treatment for two renal arteries. 
Discussion
Sympathetic hyperactivity plays a relevant role 
in the development, maintenance, and worsening of 
ventricular arrhythmias.1 RSD appeared as a safe and 
effective adjunctive therapy in the treatment of resis-
tant hypertension, and is currently under investigation 
in other clinical conditions associated with increased 
sympathetic tone, such as cardiac arrhythmias. This 
report shows the first case of refractory arrhythmia in 
a patient with Chagas disease, treated with RSD using 
a dedicated system.
In the atrium, the autonomic nervous system influ-
ences chronotropism and dromotropism. It has been 
well established that sympathetic activation increases 
the heart rate and facilitates atrioventricular conduction. 
Conversely, parasympathetic activity has opposite effects.3 
In the ventricles, increased sympathetic tone reduces ven-
tricular effective refractory period, increases automaticity, 
and decreases the threshold for ventricular arrhythmias.4
Despite the implementation of socioeconomic 
measures and development of drugs that allow for the 
treatment of the acute phase of the disease, chronic 
Chagas cardiomyopathy remains a major public health 
problem in many Latin American countries. This dis-
ease affects approximately 15 to 16 million individu-
als and is responsible for about 20,000 deaths a year 
worldwide.5 Approximately two-thirds of patients with 
chronic symptoms develop heart lesions, including 
ventricular dilation and severe ventricular dysfunction, 
tachyarrhythmia, bradyarrhythmia, and often, sudden 
death.6 The arrhythmogenic nature of Chagas disease 
is related to the presence of fibrous tissue intertwined 
with areas of preserved myocardium and dyskinetic 
regions, creating a territory with high propensity to 
complex ventricular arrhythmias. Sustained VT/VF is 
the leading cause of death from this disease. Rates of 
sudden death are responsible for approximately 55% 
to 65% of the total mortality in patients with Chagas’ 
disease, superior to mortality rates due to heart failure.7 
Ukena et al.8 reported the first experience with 
RSD in electrical storm in two patients with heart 
failure: a patient with hypertrophic cardiomyopathy 
and monomorphic VT, despite the use of antiarrhyth-
mics and unsuccessfully performed endocardial and 
epicardial cardiac ablation; and another with dilated 
cardiomyopathy and frequent episodes of VF/polymor-
phic VT, who refused to undergo cardiac ablation. In 
both cases, the RSD resulted in significant reduction 
in the arrhythmic burden.
Staico et al.9 recently reported a substantial reduc-
tion in VT and appropriate ICD therapies in a patient 
with dilated cardiomyopathy and contraindication to 
cardiac ablation (left ventricular thrombus) submitted 
to RSD. Notably, this patient had three accessory renal 
arteries and, due to the small diameter, only one was 
treated, in addition to the main renal arteries.
It is possible that in addition to its action on the 
autonomic tone, the RSD could result in effects second-
ary to the reduction in excess volume and hormonal 
activation involved in heart failure. The pilot study 
Olomouc-1, presented at the Congress of the European 
Society of Cardiology in 2012, compared the effects 
of RSD to optimal medical therapy in 51 patients 
with advanced heart failure, and demonstrated that in 
addition to reducing the left ventricular dimensions, 
the RSD reduced the autonomic tone and mean heart 
rate. However, in the present case, the patient had no 
ventricular dysfunction, suggesting that the reduction of 
arrhythmia was related to autonomic tone modulation.
Even though there are yet no definitive recommen-
dations, the importance of sympathetic hyperactivity in 
patients with ventricular arrhythmias is clear. The study 
illustrates the feasibility and potential effectiveness of 
RSD in this scenario. Larger clinical trials on the impact 
of RSD on arrhythmias are in progress. If its safety and 
efficacy are demonstrated in the control of ventricular 
arrhythmias, RSD can become an interesting strategy 
for the treatment these patients.
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